Prostatic Neoplasms

137 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Prostatic Neoplasms
Treatment and conditionWhere it standsTrials
[11C]AZ1419 3391 + Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[68Ga]Ga-OncoACP3 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ABIRATERONE ACETATE + Prednisone for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
abiraterone acetate with prednisone + Tinengotinib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acupuncture + Questionnaires for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AMXI-5001:Dose Escalation Phase I + AMXI-5001:Dose Expansion Phase II for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Placebo for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy + Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aspirin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin + Aspirin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Berzosertib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Cystoscopy + Bone Scan + Digital Rectal Examination + MRI-Guided Transurethral Ultrasound Ablation + Multiparametric Magnetic Resonance Imaging + PSMA PET Scan + Questionnaire Administration for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardio-Oncology Referral for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clomiphene Citrate 25mg for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
D Vitamin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Darolutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Disitamab for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Disitamab + ENVAFOLIMAB for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
dMD-002 for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enoblituzumab for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Enzalutamide + Mevrometostat for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + PEMBROLIZUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Tinengotinib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX-19477 for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exercise Intervention for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exercise Therapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Experimental for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fasudil hydrochloride combined with immunotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLUDEOXYGLUCOSE F-18 + PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical) for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Focal One high intensity focused ultrasound device for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
GALUNISERTIB + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GSK5471713 for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
INR101 for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JNJ-101556143 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Hypofractionated Radiation Therapy + Positron Emission Tomography + Survey Administration for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Positron Emission Tomography + Stereotactic Body Radiation Therapy + Survey Administration for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Multiparametric Magnetic Resonance Imaging + Positron Emission Tomography + Transrectal Ultrasonography Guided Biopsy + Flotufolastat F-18 Gallium for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MR-Guided Transurethral US Ablation of Prostate Tissue for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MRI-Guided Transurethral Ultrasound Ablation for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NanoKnife System for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
NeuroSAFE procedure for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistantPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Padeliporfin for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PIFLUFOLASTAT F-18 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PSMA-guided Salvage Radiation for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
QLH12016 + Enzalutamide + ABIRATERONE ACETATE for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Questionnaires + Waitlist Control for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + Radical Prostatectomy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Olaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Relugolix for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Risvutatug rezetecan (Ris-Rez) for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Robot-Assisted Radical Prostatectomy + ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rocuronium 1.5mg/kg/hr for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care SBRT and ADT + ABIRATERONE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
talazoparib plus enzalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Telesurgery utilizing Microport Medbot Robotic Platform for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Terbium 161- PSMA I&T for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Testosterone for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
treatment with focal HIFU for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Triptorelin pamoate for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TULSA Procedure for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tulsa-pro for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Xaluritamig for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1